Literature DB >> 11473025

Glucose induces beta-cell apoptosis via upregulation of the Fas receptor in human islets.

K Maedler1, G A Spinas, R Lehmann, P Sergeev, M Weber, A Fontana, N Kaiser, M Y Donath.   

Abstract

In autoimmune type 1 diabetes, Fas-to-Fas-ligand (FasL) interaction may represent one of the essential pro-apoptotic pathways leading to a loss of pancreatic beta-cells. In the advanced stages of type 2 diabetes, a decline in beta-cell mass is also observed, but its mechanism is not known. Human islets normally express FasL but not the Fas receptor. We observed upregulation of Fas in beta-cells of type 2 diabetic patients relative to nondiabetic control subjects. In vitro exposure of islets from nondiabetic organ donors to high glucose levels induced Fas expression, caspase-8 and -3 activation, and beta-cell apoptosis. The effect of glucose was blocked by an antagonistic anti-Fas antibody, indicating that glucose-induced apoptosis is due to interaction between the constitutively expressed FasL and the upregulated Fas. These results support a new role for glucose in regulating Fas expression in human beta-cells. Upregulation of the Fas receptor by elevated glucose levels may contribute to beta-cell destruction by the constitutively expressed FasL independent of an autoimmune reaction, thus providing a link between type 1 and type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11473025     DOI: 10.2337/diabetes.50.8.1683

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  99 in total

1.  Deletion of Fas protects islet beta cells from cytotoxic effects of human islet amyloid polypeptide.

Authors:  Y J Park; S Lee; T J Kieffer; G L Warnock; N Safikhan; M Speck; Z Hao; M Woo; L Marzban
Journal:  Diabetologia       Date:  2012-02-01       Impact factor: 10.122

Review 2.  An immune origin of type 2 diabetes?

Authors:  H Kolb; T Mandrup-Poulsen
Journal:  Diabetologia       Date:  2005-04-30       Impact factor: 10.122

Review 3.  Islet beta cell failure in type 2 diabetes.

Authors:  Marc Prentki; Christopher J Nolan
Journal:  J Clin Invest       Date:  2006-07       Impact factor: 14.808

4.  Type 1, type 1.5, and type 2 diabetes: NOD the diabetes we thought it was.

Authors:  Marc Y Donath; Jan A Ehses
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-07       Impact factor: 11.205

5.  Gender and genetic differences in bladder smooth muscle PPAR mRNA in a porcine model of the metabolic syndrome.

Authors:  Heather M Mattern; Pamela G Lloyd; Michael Sturek; Christopher D Hardin
Journal:  Mol Cell Biochem       Date:  2007-02-21       Impact factor: 3.396

Review 6.  The role of FOXO1 in β-cell failure and type 2 diabetes mellitus.

Authors:  Tadahiro Kitamura
Journal:  Nat Rev Endocrinol       Date:  2013-08-20       Impact factor: 43.330

7.  Genetics of new-onset diabetes after transplantation.

Authors:  Jennifer A McCaughan; Amy Jayne McKnight; Alexander P Maxwell
Journal:  J Am Soc Nephrol       Date:  2013-12-05       Impact factor: 10.121

8.  Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets.

Authors:  Kathrin Maedler; Pavel Sergeev; Frédéric Ris; José Oberholzer; Helen I Joller-Jemelka; Giatgen A Spinas; Nurit Kaiser; Philippe A Halban; Marc Y Donath
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

9.  Insulin resistance is a risk factor for progression to type 1 diabetes.

Authors:  S Fourlanos; P Narendran; G B Byrnes; P G Colman; L C Harrison
Journal:  Diabetologia       Date:  2004-10-06       Impact factor: 10.122

10.  Protective role of the ELOVL2/docosahexaenoic acid axis in glucolipotoxicity-induced apoptosis in rodent beta cells and human islets.

Authors:  Lara Bellini; Mélanie Campana; Claude Rouch; Marta Chacinska; Marco Bugliani; Kelly Meneyrol; Isabelle Hainault; Véronique Lenoir; Jessica Denom; Julien Véret; Nadim Kassis; Bernard Thorens; Mark Ibberson; Piero Marchetti; Agnieszka Blachnio-Zabielska; Céline Cruciani-Guglielmacci; Carina Prip-Buus; Christophe Magnan; Hervé Le Stunff
Journal:  Diabetologia       Date:  2018-05-12       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.